Fig. 1

A Total number of BC-LMD cases seen at Moffitt Cancer Center between 2011 and 2020, by breast cancer subtype. B The proportion of BC-LMD patients to total breast cancer patients seen at Moffitt Cancer Center between 2011 and 2015 and 2016–2020. A significantly higher proportion of (BC-LMD patients)/(Total Breast Cancer Patients) was observed in the latter half of the decade (p = 0.0168). HR + Hormone Receptor Positive; HER2 + Human Epidermal Growth Factor Receptor 2-Positive; TNBC Triple Negative Breast Cancer; BC-LMD Breast Cancer Leptomeningeal Disease